ERBB2 and breast carcinoma: The efficacy of bevacizumab combined with two chemotherapeutic agents was generally superior to bevacizumab combined with mono-chemotherapy on ORR, but there was no significant difference on PFS in patients with HER2-negative breast cancer [16–18].